株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬剤溶出ステント (DES):医療機器のパイプライン評価

Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2016

発行 GlobalData 商品コード 328676
出版日 ページ情報 英文 268 Pages
即納可能
価格
本日の銀行送金レート: 1USD=116.15円で換算しております。
Back to Top
薬剤溶出ステント (DES):医療機器のパイプライン評価 Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2016
出版日: 2016年12月05日 ページ情報: 英文 268 Pages
概要

当レポートでは、世界の薬剤溶出ステント (DES) 市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 先進創傷管理の概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 薬剤溶出ステント (DES) :各企業で現在治験中のパイプライン製品

  • 薬剤溶出ステントの企業:治験段階別のパイプライン製品
  • 薬剤溶出ステント:治験段階別のパイプライン製品

第5章 薬剤溶出ステント (DES) の企業・製品の概要

  • Aachen Resonance GmbH
    • パイプライン製品および進行中の治験の概要
  • Abbott Vascular Inc.
  • Adcomp Technologies Inc.
  • Aeon Bioscience
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical Inc
  • Arravasc Ltd
  • B. Braun Melsungen AG
  • Biosensors International Group Ltd
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • Cardionovum GmbH
  • CARDIOREV PTE. LTD
  • Columbia University
  • Contego Medical, LLC
  • Cordis Corp
  • DISA Vascular (Pty) Ltd.
  • Divya Laboratories
  • Elixir Medical Corp
  • Envision Scientific Pvt. Ltd
  • I.B.S. S.p.A.
  • InspireMD Inc
  • カネカ
  • Lepu Medical Technology (Beijing) Co Ltd
  • Medinol Ltd
  • Medlogics Device Corp
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • Micell Technologies Inc
  • MicroPort Scientific Corp
  • Minvasys
  • MIV Therapeutics Inc
  • Northwestern University
  • NuVascular Technologies Inc
  • OrbusNeich
  • Relisys Medical Devices Ltd
  • REVA Medical Inc
  • Rontis AG
  • Sino Medical-Device Technology Co., Ltd.
  • Stentys SA
  • Svelte Medical Systems, Inc.
  • テルモ
  • Tryton Medical Inc
  • University of Alabama at Birmingham
  • University of Florida
  • University of Strathclyde
  • Vascular Concepts Ltd
  • Zorion Medical

第6章 薬剤溶出ステント (DES) 市場:昨今の動向 (全62件)

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0300EPD

GlobalData's Medical Devices sector report, "Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2016" provides an overview of Drug Eluting Stents (DES) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Eluting Stents (DES) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Drug Eluting Stents (DES) Overview

3. Products under Development

  • 3.1. Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • 3.2. Drug Eluting Stents (DES) - Pipeline Products by Territory
  • 3.3. Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • 3.4. Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • 3.5. Drug Eluting Stents (DES) - Ongoing Clinical Trials

4. Drug Eluting Stents (DES) - Pipeline Products under Development by Companies

  • 4.1. Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • 4.2. Drug Eluting Stents (DES) - Pipeline Products by Stage of Development

5. Drug Eluting Stents (DES) Companies and Product Overview

  • 5.1. Aachen Resonance GmbH Company Overview
    • 5.1.1. Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Abbott Vascular Inc. Company Overview
    • 5.2.1. Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Adcomp Technologies Inc. Company Overview
    • 5.3.1. Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Aeon Bioscience Company Overview
    • 5.4.1. Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. AlviMedica Medical Technologies Inc. Company Overview
    • 5.5.1. AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Amaranth Medical Inc Company Overview
    • 5.6.1. Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Arravasc Ltd Company Overview
    • 5.7.1. Arravasc Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. B. Braun Melsungen AG Company Overview
    • 5.8.1. B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Biosensors International Group Ltd Company Overview
    • 5.9.1. Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Biotronik SE & Co KG Company Overview
    • 5.10.1. Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Boston Scientific Corp Company Overview
    • 5.11.1. Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Cardionovum GmbH Company Overview
    • 5.12.1. Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. CARDIOREV PTE. LTD Company Overview
    • 5.13.1. CARDIOREV PTE. LTD Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Columbia University Company Overview
    • 5.14.1. Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Contego Medical, LLC Company Overview
    • 5.15.1. Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. Cordis Corp Company Overview
    • 5.16.1. Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. DISA Vascular (Pty) Ltd. Company Overview
    • 5.17.1. DISA Vascular (Pty) Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Divya Laboratories Company Overview
    • 5.18.1. Divya Laboratories Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Elixir Medical Corp Company Overview
    • 5.19.1. Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Envision Scientific Pvt. Ltd Company Overview
    • 5.20.1. Envision Scientific Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. I.B.S. S.p.A. Company Overview
    • 5.21.1. I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. InspireMD Inc Company Overview
    • 5.22.1. InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Kaneka Corp Company Overview
    • 5.23.1. Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Lepu Medical Technology (Beijing) Co Ltd Company Overview
    • 5.24.1. Lepu Medical Technology (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Medinol Ltd Company Overview
    • 5.25.1. Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Medlogics Device Corp Company Overview
    • 5.26.1. Medlogics Device Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. Medtronic plc Company Overview
    • 5.27.1. Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. Meril Life Sciences Pvt Ltd Company Overview
    • 5.28.1. Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. Micell Technologies Inc Company Overview
    • 5.29.1. Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. MicroPort Scientific Corp Company Overview
    • 5.30.1. MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. Minvasys Company Overview
    • 5.31.1. Minvasys Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. MIV Therapeutics Inc Company Overview
    • 5.32.1. MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33. Northwestern University Company Overview
    • 5.33.1. Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.34. NuVascular Technologies Inc Company Overview
    • 5.34.1. NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.35. OrbusNeich Company Overview
    • 5.35.1. OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • 5.36. Relisys Medical Devices Ltd Company Overview
    • 5.36.1. Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.37. REVA Medical Inc Company Overview
    • 5.37.1. REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.38. Rontis AG Company Overview
    • 5.38.1. Rontis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.39. Sino Medical-Device Technology Co., Ltd. Company Overview
    • 5.39.1. Sino Medical-Device Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.40. Stentys SA Company Overview
    • 5.40.1. Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.41. Svelte Medical Systems, Inc. Company Overview
    • 5.41.1. Svelte Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.42. Terumo Corp Company Overview
    • 5.42.1. Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.43. Tryton Medical Inc Company Overview
    • 5.43.1. Tryton Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.44. University of Alabama at Birmingham Company Overview
    • 5.44.1. University of Alabama at Birmingham Pipeline Products & Ongoing Clinical Trials Overview
  • 5.45. University of Florida Company Overview
    • 5.45.1. University of Florida Pipeline Products & Ongoing Clinical Trials Overview
  • 5.46. University of Strathclyde Company Overview
    • 5.46.1. University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
  • 5.47. Vascular Concepts Ltd Company Overview
    • 5.47.1. Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.48. Zorion Medical Company Overview
    • 5.48.1. Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview

6. Drug Eluting Stents (DES)- Recent Developments

  • 6.1. Nov 28, 2016: Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan
  • 6.2. Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
  • 6.3. Nov 21, 2016: OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing
  • 6.4. Nov 18, 2016: MicroPort's Firesorb Stars in TCT 2016
  • 6.5. Nov 18, 2016: MicroPort's Firehawk Stars in TCT 2016
  • 6.6. Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
  • 6.7. Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction
  • 6.8. Nov 14, 2016: InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016
  • 6.9. Nov 07, 2016: Medinol receives approval from the Japanese PMDA to begin clinical study on novel DES
  • 6.10. Nov 07, 2016: ARIAD Reports Third Quarter 2016 Financial Results
  • 6.11. Nov 01, 2016: TCT 2016: Physicians Share Positive Experiences with Magmaris Resorbable Scaffold at Symposium
  • 6.12. Oct 31, 2016: First Clinical Data of Medtronic Drug-Filled Stent Show Positive Outcomes
  • 6.13. Oct 31, 2016: TCT 2016: Orsiro Drug-Eluting Stent Proves Non-Inferiority to Resolute Integrity and Synergy Stents
  • 6.14. Oct 31, 2016: Positive Five-Year Clinical Data from Micell Technologies' MiStent Presented at TCT 2016
  • 6.15. Oct 31, 2016: Svelte Medical Systems Announces Start of DIRECT III Post-Market Registry Study
  • 6.16. Oct 30, 2016: Independent Study Finds Biodegradable Polymer Stents Provide No Clinical Benefit Over Resolute Integrity DES
  • 6.17. Oct 28, 2016: Tryton Medical Enters Into Strategic Agreement with Cardinal Health
  • 6.18. Oct 28, 2016: MicroPort Wins Annual PMO Award of PMI (China)
  • 6.19. Oct 28, 2016: REVA Medical: Quarter Ended 30 September 2016
  • 6.20. Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
  • 6.21. Oct 24, 2016: Svelte Medical Systems Announces CE Mark Certification of DIRECT RX
  • 6.22. Oct 19, 2016: Firehawk Receives South Korea KGMP Certification
  • 6.23. Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results
  • 6.24. Oct 19, 2016: Elixir Medical Announces Schedule of Programs for TCT 2016
  • 6.25. Oct 17, 2016: Tryton Medical Announces Clinical Symposium on Treatment of Complex Bifurcation Lesions at TCT 2016
  • 6.26. Oct 17, 2016: First Firehawk Implantation in Pakistan Completed
  • 6.27. Oct 17, 2016: MicroPort Concludes Enrollment In Randomized, Multicenter, European Study Of Firehawk Coronary Stent System
  • 6.28. Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • 6.29. Sep 29, 2016: BIOTRONIK Begins Manufacturing High-Tech Products in Singapore
  • 6.30. Sep 15, 2016: STENTYS Reports 2016 First-Half Results
  • 6.31. Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
  • 6.32. Sep 12, 2016: Firehawk Receives Regulatory Approval in Pakistan
  • 6.33. Sep 07, 2016: InspireMD Appoints Thomas Kester to Board of Directors
  • 6.34. Sep 01, 2016: First Firehawk Implantation in East Europe Completed
  • 6.35. Aug 30, 2016: BASKET-SAVAGE trial: Drug-eluting stents more benefit in saphenous vein grafts
  • 6.36. Aug 30, 2016: MPSC Announces 2016 Interim Results
  • 6.37. Aug 25, 2016: Medtronic Reports First Quarter Financial Results
  • 6.38. Aug 24, 2016: Firehawk Granted Market Launch in Vietnam
  • 6.39. Aug 24, 2016: Innovation, Translation, and Cooperation: MicroPort Attends CHC 2016 to Present Firehawk
  • 6.40. Aug 15, 2016: Firehawk Approved for Market Launch in Argentina
  • 6.41. Aug 09, 2016: InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2016
  • 6.42. Jul 29, 2016: REVA Medical: Quarter Ended 30 June 2016
  • 6.43. Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
  • 6.44. Jul 28, 2016: ARIAD Reports Second Quarter and First Half 2016 Financial Results
  • 6.45. Jul 21, 2016: Firehawk Granted Market Approval in India
  • 6.46. Jul 21, 2016: Svelte Medical Systems Raises USD4 Million in Venture Financing
  • 6.47. Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results
  • 6.48. Jul 19, 2016: STENTYS Enrolls First Patient in Left Main Clinical Trial
  • 6.49. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.50. Jul 12, 2016: STENTYS: 41% Increase in Revenues in the Second Quarter of 2016
  • 6.51. Jul 05, 2016: Outcomes from Tryton Medical Pivotal Confirmatory Study Published in JACC Cardiovascular Interventions
  • 6.52. Jul 04, 2016: STENTYS: Appointment of Cardiolovascular Device Veteran as New CEO
  • 6.53. Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic
  • 6.54. Jun 29, 2016: InspireMD Raises USD14.6 Million in Public Offering of Preferred Stock and Warrants
  • 6.55. Jun 20, 2016: Micell Technologies Raises USD25.8 Million in Venture Financing
  • 6.56. Jun 17, 2016: ARIAD Completes Strategic Review and Announces Plans for Growth
  • 6.57. Jun 15, 2016: BIOTRONIK Announces CE Mark for Magmaris, the First Clinically Proven Bioresorbable Magnesium Scaffold
  • 6.58. Jun 08, 2016: STENTYS Announces CE Marking Of Its Longest Xposition Stent
  • 6.59. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.60. Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day
  • 6.61. Jun 03, 2016: Lepu Medical Releases Updates of Clinical trial results of NeoVas Stent in EuroPCR 2016
  • 6.62. Jun 03, 2016: LEPUCARE established in India

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Table 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Table 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Table 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Table 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Table 6: Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • Table 7: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Table 8: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: ARtax Coronary Stent - Product Status
  • Table 10: ARtax Coronary Stent - Product Description
  • Table 11: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: AVJ-09-385 Everolimus Eluting Coronary Stent System - Product Status
  • Table 13: AVJ-09-385 Everolimus Eluting Coronary Stent System - Product Description
  • Table 14: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
  • Table 15: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
  • Table 16: XIENCE Thinman DES - Product Status
  • Table 17: XIENCE Thinman DES - Product Description
  • Table 18: ZoMaxx Drug Eluting Coronary Stent System - Product Status
  • Table 19: ZoMaxx Drug Eluting Coronary Stent System - Product Description
  • Table 20: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Dual Drug Eluting Stent - Product Status
  • Table 22: Dual Drug Eluting Stent - Product Description
  • Table 23: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Drug Eluting Stent - Product Status
  • Table 25: Drug Eluting Stent - Product Description
  • Table 26: AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Cre8 DES - Product Status
  • Table 28: Cre8 DES - Product Description
  • Table 29: DES - Coracto - Product Status
  • Table 30: DES - Coracto - Product Description
  • Table 31: Janus Flex - Product Status
  • Table 32: Janus Flex - Product Description
  • Table 33: Optima Jet - Product Status
  • Table 34: Optima Jet - Product Description
  • Table 35: AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview
  • Table 36: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
  • Table 37: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
  • Table 38: Cre8 DES - A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
  • Table 39: Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: MAGNITUDE Scaffold - Product Status
  • Table 41: MAGNITUDE Scaffold - Product Description
  • Table 42: Amaranth Medical Inc - Ongoing Clinical Trials Overview
  • Table 43: MAGNITUDE Scaffold - Clinical Study of Fourth-generation MAGNITUDE Scaffold
  • Table 44: MAGNITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
  • Table 45: Arravasc Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: Sideguard - Product Status
  • Table 47: Sideguard - Product Description
  • Table 48: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Coroflex DEBlue - Product Status
  • Table 50: Coroflex DEBlue - Product Description
  • Table 51: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: BioFreedom Drug Coated Stent - Product Status
  • Table 53: BioFreedom Drug Coated Stent - Product Description
  • Table 54: Excel II DES - Product Status
  • Table 55: Excel II DES - Product Description
  • Table 56: Sparrow Drug Eluting Stent System - Product Status
  • Table 57: Sparrow Drug Eluting Stent System - Product Description
  • Table 58: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
  • Table 59: Sparrow Drug Eluting Stent System - CARE II Clinical Trial
  • Table 60: BioFreedom Drug Coated Stent - A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent versus the Gazelle Bare Metal Stent in Patients with High Risk of Bleeding
  • Table 61: BioFreedom Drug Coated Stent - A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
  • Table 62: BioFreedom Drug Coated Stent - A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions
  • Table 63: BioFreedom Drug Coated Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
  • Table 64: BioFreedom Drug Coated Stent - Randomized Comparison of Vascular Healing of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
  • Table 65: BioFreedom Drug Coated Stent - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease
  • Table 66: Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
  • Table 67: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: Orsiro Hybrid Drug Eluting Stent - Product Status
  • Table 69: Orsiro Hybrid Drug Eluting Stent - Product Description
  • Table 70: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status
  • Table 71: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Description
  • Table 72: Biotronik SE & Co KG - Ongoing Clinical Trials Overview
  • Table 73: Orsiro Hybrid Drug Eluting Stent - A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-eluting Stent with a Durable Polymer Everolimus-eluting Stent for Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • Table 74: Orsiro Hybrid Drug Eluting Stent - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial with Stent Evaluation in All-comers IV (TWENTE IV)
  • Table 75: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment of Subjects with up to Three De Novo or Restenotic Coronary Artery Lesions - V
  • Table 76: Orsiro Hybrid Drug Eluting Stent - Biotronik - Safety and Performance Registry for an All-comers Diabetic Patient Population with the Limus Eluting Orsiro Stent System Within Daily Clinical Practice-III Asia
  • Table 77: Orsiro Hybrid Drug Eluting Stent - Biotronik - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium
  • Table 78: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite
  • Table 79: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III Hungary
  • Table 80: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III United Kingdom Satellite
  • Table 81: Orsiro Hybrid Drug Eluting Stent - Biotronik- Safety and Performance Registry for an all Comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice III- Eladis
  • Table 82: Orsiro Hybrid Drug Eluting Stent - Biotronik-A Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to Two de Novo Coronary Artery Lesions - IV
  • Table 83: Orsiro Hybrid Drug Eluting Stent - BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects with de Novo Coronary Artery Lesions-VI
  • Table 84: Orsiro Hybrid Drug Eluting Stent - Comparison of Biodegradable Polymer and Durable Polymer Drug-eluting Stents in an All Comers Population: Randomized Multicenter Trial in an All Comers Population Treated within the Netherlands 3 (TWENTE 3)
  • Table 85: Orsiro Hybrid Drug Eluting Stent - Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients with All-comer Patients with Coronary Artery Disease : A Multicenter, Randomized, Open Label Study (BIODEGRADE Study)
  • Table 86: Orsiro Hybrid Drug Eluting Stent - Evaluation of Effectiveness and Safety of Orsiro in Routine Clinical Practice: A Multicenter, Prospective Observational Study
  • Table 87: Orsiro Hybrid Drug Eluting Stent - Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention with Next Generation Drug-eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
  • Table 88: Orsiro Hybrid Drug Eluting Stent - Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV)
  • Table 89: Orsiro Hybrid Drug Eluting Stent - Prospective, Single-center, Randomized Trial, Intended to Compare of Intravascular Ultrasound and Optical Coherence Tomography Guided Implantation of Different Drug-eluting Stents and Implantation without Using of Intravascular Visualization
  • Table 90: Orsiro Hybrid Drug Eluting Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
  • Table 91: Orsiro Hybrid Drug Eluting Stent - Randomized Comparison of Vascular Healing of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
  • Table 92: Orsiro Hybrid Drug Eluting Stent - Safety and Performance Registry for an All Comers Patient Population with the Limus Eluting Orsiro Stent Within Daily Clinical Practice III -Italy
  • Table 93: Orsiro Hybrid Drug Eluting Stent - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada
  • Table 94: Orsiro Hybrid Drug Eluting Stent - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System within Daily Clinical Practice - III Russia
  • Table 95: Orsiro Hybrid Drug Eluting Stent - The Comparison of Strategies to PREPARE Severely CalCified Coronary Lesions Trial (PREPARE-CALC): A Prospective Randomized Controlled Trial of Rotational Atherectomy Versus Cutting/Scoring Balloon in Severely Calcified Coronary Lesions
  • Table 96: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Innova Peripheral Vascular Drug-Eluting Stent System - Product Status
  • Table 98: Innova Peripheral Vascular Drug-Eluting Stent System - Product Description
  • Table 99: JACTAX Drug Eluting Stent - Product Status
  • Table 100: JACTAX Drug Eluting Stent - Product Description
  • Table 101: Odyssey - Product Status
  • Table 102: Odyssey - Product Description
  • Table 103: TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Status
  • Table 104: TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Description
  • Table 105: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: PROTECT - Product Status
  • Table 107: PROTECT - Product Description
  • Table 108: CARDIOREV PTE. LTD Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: Peptide-Eluting Coronary Stent - Product Status
  • Table 110: Peptide-Eluting Coronary Stent - Product Description
  • Table 111: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: C3 Exoenzyme Coated Stent - Product Status
  • Table 113: C3 Exoenzyme Coated Stent - Product Description
  • Table 114: Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: CORGUARD - Product Status
  • Table 116: CORGUARD - Product Description
  • Table 117: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Corio Pimecrolimus-eluting Stent - Product Status
  • Table 119: Corio Pimecrolimus-eluting Stent - Product Description
  • Table 120: CYPHER ELITE - Product Status

List of Figures

  • Figure 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Figure 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Figure 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Figure 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Figure 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Back to Top